2. Academic Validation
  3. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

  • Bioorg Med Chem. 2003 May 29;11(11):2427-37. doi: 10.1016/s0968-0896(03)00126-3.
Tomoyasu Ishikawa 1,  Nobuyuki Matsunaga,  Hiroyuki Tawada,  Noritaka Kuroda,  Yutaka Nakayama,  Yukio Ishibashi,  Mitsumi Tomimoto,  Yukihiro Ikeda,  Yoshihiko Tagawa,  Yuji Iizawa,  Kenji Okonogi,  Shohei Hashiguchi,  Akio Miyake
Affiliations

Affiliation

  • 1 Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., 2-17-85 Jusohonmachi, Yodogawa-ku, 532-8686, Osaka, Japan. ishikawa_tomoyasu@takeda.co.jp
PMID: 12735989 DOI: 10.1016/s0968-0896(03)00126-3
Abstract

Crystalline 1 (TAK-599) is a novel N-phosphono prodrug of anti-methicillin-resistant Staphylococcus aureus (MRSA) cephalosporin 2a (T-91825) that has high affinity for penicillin-binding protein (PBP) 2' (IC(50); 0.90 microg/mL) and shows potent in vitro anti-MRSA activity (MIC against MRSA N133; 1.56 microg/mL), comparable to that of vancomycin (1.56 microg/mL). Although 2a had insufficient water solubility (2.3 mg/mL) for parenteral administration, 1 showed excellent water solubility (>100 mg/mL, pH 7) as well as good chemical stability in the solid state and solution. In pharmacokinetic studies, when 1 was administered intravenously to rats and monkeys, it was rapidly converted into 2a in the blood. These results show that 1 (TAK-599) is a highly promising parenteral cephalosporin targeted for MRSA Infection.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z